Led · Equity · Sep 2025

Founded in 2022, Mamedica operates a digital-first healthcare platform that connects UK patients with specialist clinicians for video consultations and subsequent delivery of regulated cannabis-based medicines. The company focuses on treating chronic and neurological conditions such as pain, anxiety, ADHD and depression, and now covers pain, psychiatry, neurology, palliative care and cancer. Since launch, it has treated more than 10,000 patients, with roughly 7,500 currently under active care and about 10% month-on-month growth in new consultations. Patient numbers grew 1,250% in 2023 and 154% in 2024, and management expects to double the patient base annually as the UK medical cannabis market approaches a projected £1 billion in sales by 2028. Mamedica’s proprietary platform automates workflows, ensures compliance and integrates dispensing, with medication delivered by secure next-day courier. The new capital will be directed toward optimising the in-house supply chain, expanding the clinical network, enhancing the digital platform’s automation and compliance features, and funding education to help integrate medical cannabis into mainstream UK healthcare.

Led · Seed · Aug 2024

Growlink is a Denver, CO-based controlled environment agriculture (CEA) provider of advanced IoT controllers, sensors, and cultivation software. The platform leverages AI and IoT technologies to deliver precise climate control, automated irrigation, nutrient delivery, and data analytics for cannabis cultivation. The company has operated profitably for the past 10 years without any external funding or debt and serves over 2,200 active locations in 35 countries, including a majority of US-based multi-state operators. Growlink is led by CEO Ted Tanner. The company intends to use the funds to expand its AI capabilities and enhance its third-party integration platform so any hardware can connect to the Growlink cloud. Users will gain access to advanced control algorithms, cultivar blueprints, and AI crop steering programs; current integrations include Agrowtek, Trolmaster, Pulse Grow, and Aranet wireless sensors.

Led · Seed · Nov 2023

Prelude is an NYC-based provider of an AI-powered supply chain solution for the cannabis ecosystem. Co-founded by Michael E. Murphy and Andrew Copp, the company’s product is purpose-built to reduce out-of-stocks and overstocks at dispensaries to improve sales, profitability, and cash flow. Prelude is currently focused on the retail layer, helping dispensaries decide which products to buy and in what quantities to optimize inventory assortments and administrative costs. It plans to extend the same value across the entire supply chain, from seed to sale and every step in between. The company recently raised seed funding to support these efforts and expand its market presence.

Led · Seed · Aug 2023

Frontier Risk is a digital broker focused on providing insurance coverages for companies in the cannabis sector. Its core product is a tech-enabled insurance platform and ecosystem intended to better service cannabis risk. The company is led by CEO James Whitcomb, the former CEO of Parallel, and its team includes former employees of Intact, Munich Re, and Embroker. Frontier Risk says the capital and investor expertise will help it expand its platform across the cannabis industry and pursue risk-management solutions for alternative wellness. The company recently closed a Seed financing round to support those expansion plans and product development. No operating metrics or revenue figures were disclosed in the articles.

Participated · Series B · Sep 2022

Sanity Group, founded in Berlin in 2018, develops medicinal cannabis, wellbeing and cosmetic cannabinoid products and operates brands/subsidiaries such as AVAAY Medical, Vayamed, Endosane Pharmaceuticals and VAAY. The company maintains a large German distribution network of over 2,000 pharmacies and works with approximately 5,000 physicians, holding roughly a 10% share of the German medical cannabis market; its AVAAY medical brand is estimated to be number two. Sanity is participating in a Swiss recreational cannabis pilot in Basel with one store operational and plans to expand its retail footprint in Switzerland. The company intends to invest in proprietary distribution channels to capture new medical consumers and is planning initiatives expected to provide access to over 100,000 patients and support recreational pilot expansion. Sanity’s product mix spans pharmaceuticals, medical cannabis, and wellbeing/cosmetic offerings, and it operates a storage facility near Frankfurt for extracts and flower. Sanity Group develops medicinal cannabis, finished pharmaceuticals, medical products, digital applications, wellbeing products and natural cosmetics that utilize cannabinoids and the endocannabinoid system. The group comprises Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). It operates a production and processing facility for cannabis extracts near Frankfurt am Main and employs around 120 people across medical, consumer health and science functions. Founded in Berlin in 2018, the company aims to improve quality of life through cannabinoid-based products and therapies. Sanity Group plans to use new funding to accelerate growth, enable European expansion and strengthen research and development. The company has raised over $100 million in total funding to date. Sanity Group is a Berlin-based cannabis and digital health startup that builds a cannabis-based platform for mental health and chronic pain management. Its offering includes a medical device and digital therapy diary that tracks administered active ingredients (THC, CBD and other cannabinoids) to quantify dosing. The company closed a $44.2M Series A, bringing total funding to $73M; the round is reported as the largest cannabis funding round in Europe to date. Proceeds will be used to expand the Group’s medical division in Europe and to build an EU‑GMP‑compliant research and production facility near Frankfurt. Management says it is expanding geographically into the Czech Republic and Poland, targeting the U.K., and expects France to open next year. Prior investors include HV Capital, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures and SevenVentures, and celebrity angels include will.i.am, Scooter Braun and Alyssa Milano. Sanity Group is a Berlin-based medical cannabis and wellness company operating two business units: Sanatio Pharma, focused on developing new medical cannabis therapies and pharmaceuticals, and VAAY, a consumer wellness brand. The company is fully licensed and currently operational. Founded in 2018 by Finn Hänsel and Fabian Friede, Sanity Group combines medical and consumer wellness offerings. It completed a €20m funding round to support strategic initiatives. The funds will be used to drive projects that expand access to medical and medically-related cannabis products and advance its product programs.